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Abstract
Background: Renal hypertrophy occurs early in diabetic nephropathy, its later value is unknown. Do large kidneys
still predict poor outcome in patients with diabetes and Chronic Kidney Disease (CKD)?
Methods: Seventy-five patients with diabetes and CKD according to a Glomerular Filtration Rate (GFR, by 51Cr-
EDTA clearance) below 60 mL/min/1.73 m
2 or an Albumin Excretion Rate above 30 mg/24 H, had an ultrasound
imaging of the kidneys and were cooperatively followed during five years by the Diabetology and Nephrology
departments of the Centre Hospitalier Universitaire de Bordeaux.
Results: The patients were mainly men (44/75), aged 62 ± 13 yrs, with long-standing diabetes (duration:17 ± 9 yrs,
55/75 type 2), and CKD: initial GFR: 56.5 (8.5-209) mL/min/1.73 m
2, AER: 196 (20-2358) mg/24 H. Their mean kidney
lenght (108 ± 13 mm, 67-147) was correlated to the GFR (r = 0.23, p < 0.05). During the follow-up, 9/11 of the
patients who had to start dialysis came from the half with the largest kidneys (LogRank: p < 0.05), despite a 40%
higher initial isotopic GFR. Serum creatinine were initially lower (Small kidneys: 125 (79-320) μmol/L, Large: 103 (50-
371), p < 0.05), but significantly increased in the “large kidneys” group at the end of the follow-up (Small kidneys:
129 (69-283) μmol/L, Large: 140 (50-952), p < 0.005 vs initial). The difference persisted in the patients with severe
renal failure (KDOQI stages 4,5).
Conclusions: Large kidneys still predict progression in advanced CKD complicating diabetes. In these patients,
ultrasound imaging not only excludes obstructive renal disease, but also provides information on the progression
of the renal disease.
Background
One third of patients with diabetes have kidney
damage [1]. The screening of Chronic Kidney Disease
(CKD) in patients with diabetes is based on the Albu-
min excretion rate (AER, threshold: 30 mg/24 H) and
the estimated Glomerular Filtration Rate (e-GFR,
threshold: 60 mL/min/1.73 m
2) [2]. Other phenomena
occur earlier in the course of diabetic nephropathy,
such as glomerular hyperfiltration [3,4], renal hypertro-
phy [5], and renal histologic lesions [6], but their
assessment in day-to-day clinical practice is inconveni-
ent: renal biopsies are invasive, GFR determinations
are expensive and GFR estimations are not useful for
diagnosis of hyperfiltration [7,8].
Ultrasound allows non-invasive renal imaging at mod-
erate expense, and it is recommended for the first line
evaluation of CKD [9], although the discovery of
obstructive renal disease or tumors is rare [10]. The
overal dimensions of the kidneys can also be determined
by ultrasonic imaging [11]. Zerbini et al have recently
shown that renal hypertrophy predicts microalbuminuria
in patients with type 1 diabetes and normal renal func-
tion [12]. Whether kidney size still predicts the progres-
sion in more advanced cases, when ultrasound imaging
is indicated in clinical practice, is unknown.
In 75 patients with diabetes and CKD, we measured
the AER, the GFR by 51Cr-EDTA clearance, and kidney
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a structured collaborative care program involving diabe-
tologists and nephrologists, and followed up for 5 years,
to determine whether their outcome (number of dialysis
onset, serum creatinine and e-GFR) differed according
to initial kidney size.
Methods
Subjects
Seventy-five patients (44 men, mean age 62 ± 13 yrs)
were recruited from the Nutrition-Diabetology and
Nephrology departments of the Centre Hospitalier Uni-
versitaire de Bordeaux. The inclusion criteria were:
1-Diabetes. Twenty patients had type 1 diabetes, 55
type 2,
2-CKD according to an AER above 30 mg/24 H or a
GFR below 60 mL/min/1.73 m2, not requiring renal
replacement therapy at inclusion,
3-An ultrasound imaging with measurement of the
length of the kidneys (Two other patients were excluded
because they only had one kidney).
The patients gave written informed consent to partici-
pate to the study, which was approved by the ethical
committee of our institution. This study was supported
by a clinical research program in the Bordeaux Univer-
sity Hospital.
Analytical methods
The AER was determined on two 24 H urine collections
during a short hospitalization, with an immunonephelo-
metric analyzer (Behring Nephelometer 2) using an
appropriate kit (Nantiserum VO human albumin, Dade
Behring). Serum creatinine was determined on a multi-
parameter analyzer (Olympus AU 640: Olympus Optical,
Tokyo, Japan) using the Jaffé method with bichromatic
measurements according to the manufacturer’s specifica-
tions, and daily calibration of the analyzer. This proce-
dure did not change in our laboratory during the study.
The GFR was estimated from serum creatinine by the
Mayo clinic quadratic equation [13]. Clearance of the
radionucleide marker was measured after intravenous
injection of 51Cr-EDTA (Cis Industries, Gif/Yvette,
France). All patients were studied in the morning at 9
am, after a light breakfast. After a single bolus of 100
μCi (3.7 MBq) of 51Cr-EDTA, four venous blood sam-
ples were withdrawn at 75, 105, 135 and 165 minutes,
and urinary samples were collected at 90, 120, 150 and
180 minutes, as previously described [14]. The final
result was the mean of the four clearance values. If for
one period the urine flow was too low or if a clearance
value was not within ± 20% of the mean of the three
others, this value was excluded and the mean was calcu-
lated for the other three clearances. Less than 5% of the
values were excluded this way. The 51Cr-EDTA
radioactivity was measured in a gamma counter
(COBRA 2, model 05003, Packard Instruments, Meri-
den, CT). The ultrasound imaging was performed in the
department of medical imaging during the same hospi-
talization., to measure the length of both kidneys.
Follow-up, care and outcome
This prospective study began on June 2001, untill
December 2008. It was based on a cooperative follow-up
between diabetologists and nephrologists with the estab-
lishment of a joint medical file for each patient. This
cooperative follow-up was complementary and included
one visit with the diabetologist every four months, and
visits with the nephrologist with intervals proportional
to the e-GFR. Mean duration of the follow-up was 61 ±
19 (min:1, max:84) months.
The care program objectives included glycemic control
according to the French 1999 recommendations (HbA1c
< 8.0%, if possible 6.5% without severe hypoglycemia in
type 2, and < 7.0% in type 1), but also control of asso-
ciated factors such as hypertension (objective: < 130/80
mmHg) and dyslipidemia (objective: LDL-cholesterol <
1.3 g/L). We have previously reported [15] that we
could obtain significant reductions of HbA1C (-0.7%,
40% of the patients reached the objective), LDL-Choles-
terol (-0.4 g/L, 70% of the patients reached the objec-
tive), and blood pressure (-10 mmHg systolic, 54% of
the patients reached the objective, -5 mmHg diastolic,
95% of the patients reached the objective - 75% were on
ACE inhibitors, Ang2 receptor inhibitors, or both), and
the Albumin Excretion Rate decreased by -40%. We pre-
scribed 0.8 g protein/kg/d according to the NKF recom-
mendations, except for patients with clinical signs of
undernutrition or who were aged 65 years and over.
The primary outcome was requirement for dialysis.
The secondary outcomes were the AER, serum creati-
nine and e-GFR at the end of the follow-up.
Statistical analysis
The results are expressed as mean ± SD, and median
(range) for the GFR, creatinine and AER which were not
normally distributed. The association between kidney
length and other variables was tested by regression ana-
lysis for continuous variables and by ANOVA and
unpaired Student’s t tests for dichotomous variables.
The subjects were then categorized as having large
(mean length > median mean length of the group) vs
small kidneys, and these two groups were compared by
ANOVA for the continuous variables, and by Chi2 for
the categorical variables. Non-parametric tests (Wil-
coxon, Mann-Witney) were used for the GFR, creatinine
and AER. For the primary outcome (dialysis onset),
prognostic curves were obtained using the Kaplan-Meier
estimation method and compared by log-rank test, the
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were censored at the end of the follow-up. A survival
analysis using the Cox proportional hazards model was
also performed to distinguish the effects of kidney
length and GFR on the risk of requiring dialysis. For the
secondary outcome, the baseline and final characteristics
of the patients were compared by paired Student t tests.
Similar analysis were performed after categorizing the
subjects as KDOQI stage 1-2,3 and 4-5 [16]. All the ana-
lysis were performed using SPSS software, version 10.0.
The significance level was fixed at p < 0.05.
Results
Baseline characteristics
Seventy five patients were included. Their mean diabetes
duration was 17 ± 9 yrs, Body Mass Index: 28.2 ± 5.3,
arterial pressure 145 ± 21/80 ± 12 mmHg, and HbA1C:
8.6 ± 1.5%. Their AER was 196 (20-2358) mg/24 H,
serum creatinine 126 (50-371) μmol/L, and isotopic
GFR was 56.5 (8.5-209) mL/min/1.73 m
2.T h e i rM C Q
e-GFR (63.8 (11-143) mL/min/1.73 m2) was slightly
higher (p < 0.05), and was well correlated with isotopic
GFR (r = 0.79, p < 0.001).
The lengths of the right (108 ± 13 mm) and left kid-
ney (108 ± 16 mm) did not differ, and were correlated
(r = 0.71, p < 0.0001). The analysis was therefore con-
ducted on the mean kidney length (108 ± 13 mm, 67-
147), which did not differ for gender or type of diabetes.
The mean kidney length was correlated with isotopic
GFR (r = 0.23, p < 0.05; figure 1). The correlations of
kidney size with age, height, BMI, HbA1C, and Albumin
excretion rate were not significant. The kidney lenght
were 100 ± 9 mm in normoalbuminuric (n = 6), 106 ±
13 mm in microalbuminuric (n = 39), and 113 ± 11 mm
in macroalbuminuric (n = 30) patients (p = 0.056).
Outcome according to kidney size
The subjects were categorized according to their mean
kidney length, as having “large” (> median = 108 mm)
or “small” kidneys. The initial characteristics of the two
groups did not differ, as shown in table 1, although
patients with large kidneys had lower serum creatinine,
higher GFR and MCQ e-GFR (all p < 0.05), as would be
expected. The higher Albumin Excretion Rate in the
“large kidneys” group almost reached significance (p =
0.052). Five years later, 9/11 of the subjects who
required dialysis (p = 0.048 by 2-sided Chi2) came from
the “large kidneys” group, despite their higher initial
GFR; these subjects are depicted as closed circles on the
figure 1. The survival curve (end-point: dialysis) is
depicted on the figure 2 (LogRank: p = 0.024). The
serum creatinine increased in the “large kidneys” group
(p = 0.002), whereas it kept stable in the “small kidneys”
group.
The eleven subjects who required dialysis during the
follow-up had lower isotopic GFR (20.4 (8.5-80) vs 59.2
(12-209) mL/min/1.73 m2 for others, p = 0.001) and lar-
ger kidneys (116 ± 19 vs 107 ± 12 mm, p = 0.042) on
inclusion. The multivariate survival analysis using the
Cox proportional hazards model showed that both
initial GFR (ExpB = 0.94, p = 0.005) and mean kidney
length (ExpB = 1.05, p = 0.02) were predictors of dialy-
sis onset. The influence of the kidney lenght did not
remain significant after adjustment for the AER.
There was no significant difference between the sub-
jects with type 1 and type 2 diabetes (gender, GFR, Albu-
min Excretion Rate, kidney lenght, HbA1C, known
duration of diabetes), except for the age and the BMI as
expected. Although the different outcomes only reached
significance for dialysis onset for type 2, according to the
restricted number of patients, the results seemed homo-
genous in both types of diabetes, as shown in the table 2.
Kidney size and outcome according to the stratification
of CKD
As shown in table 3, the kidneys tended to be smaller in
the most advanced stages of CKD (p = 0.08). The differ-
ences in progression reached significance only in the
severe renal failure groups, where all the six subjects
who had kidneys > 112 mm had to start dialysis. The
decline of e-GFR did not significantly correlate to the
kidney size (r = 0.15, p = 0,20). Twenty-one subjects
had microalbuminuria (30-300 mg/24 H) and an isoto-
pic GFR > 60 mL/min/1.73 m
2; none of them required
dialysis during the follow-up. Although the difference
was not significant, the MCQ-eGFR declined faster for
the eleven subjects with the largest (> 109 mm) kidneys:
-4.2 mL/min/1.73 m
2 (-14-+16), vs -2.3 (-6-+5) for the
10 subjects with the smaller kidneys.
Discussion
Renal hypertrophy with ~30% higher than normal kid-
ney size has been noted in type 1 diabetics [17], in some
cases after only a few days of hyperglycemia [18].
Although less common [19] and less pronounced [20], it
also exists in type 2 diabetes [21]. Since the pioneer
work of Mogensen [22,23], the high risk of microalbu-
minuria in diabetic patients with large kidneys has been
reported frequently [24-26]. This was recently empha-
zised by Zerbini et al, who demonstrated a threefold
incidence of microalbuminuria and almost threefold fas-
ter decline in GFR during the 9 years follow-up of the
highest quartile of ultrasound-measured kidneys of nor-
moalbuminuric type 1 diabetic subjects [12]. However,
all these studies were on the initial stages of renal invol-
vement. In humans, diabetic renal hypertrophy can per-
sist for years despite good glucose control [18,27-29].
But with advanced renal insufficiency the kidneys
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patients, as reflected by the correlation between GFR
and renal size as we found, in line with other authors
[12,28]. This late course raised the issue of whether kid-
ney size remained a marker of progression in diabetic
patients with more advanced CKD.
Our inclusion criterion was CKD: most of our patients
had an isotopically determined GFR below 60 mL/min/
1.73 m2, and the others had an AER above 30 mg/24 H.
The half with the largest kidneys did not differ from the
others in age, gender, diabetes duration, BMI, and the
conventional progression factors (blood pressure, AER,
HbA1C) were not significantly higher. They had 40%
higher GFR than the “small kidney” group, as expected.
High GFR has been associated with faster rates of
decline in renal function in other cohorts [31,32]. The
risk of requirement for dialysis was also associated with
kidney size after accounting for initial GFR. Clearly the
higher GFR in the “large kidney” group could not con-
tribute to the higher rate of dialysis onset, and the worst
outcome with large kidneys was still apparent after stra-
tifying the patients for CKD. Baumgartl et al also found
higher serum creatinine and more frequent dialysis
onset in 37 patients with “large kidneys” during the long
term follow-up of 73 type 1 diabetic patients with
Figure 1 Mean kidney lenght (mm) as a function (r = 0.23, p < 0.05) of isotopic GFR (mL/min/1.73 m
2). The subjects who required
dialysis during the follow-up are depicted as closed circles, the other subjects as open circles.
Table 1 Baseline and final characteristics of the subjects
according to their initial mean kidney length
(threshold = median = 108 mm)
Small Large
N3 7 3 8
Initial
Mean kidney length (mm) 98 ± 8 118 ± 10***
Age (yrs) 64 ± 12 61 ± 14
Gender (%men) 54% 63%
BMI 27.6 ± 6.0 28.7 ± 4.5
HbA1C (%) 8.8 ± 1.5 8.4 ± 1.4
Diabetes duration (yrs) 17 ± 10 16 ± 9
Blood pressure (mmHg) 147 ± 19/82 ± 12 143 ± 23/77 ± 13
AER (mg/24 H) 112 (20-2358) 390 (28-2312)
Serum creatinine (μmol/L) 125 (79-320) 103 (50-371)*
MCQ e-GFR (mL/min/1.73 m2) 58 (17-109) 73 (26-143)*
Isotopic GFR(mL/min/1.73 m2) 43(15-129) 71(8.5-209)*
End of the follow-up
Duration of follow-up (months) 61 ± 20 60 ± 19
Serum creatinine (μmol/L) 129 (69-283) 140 (50-952)
Decline in MCQ e-GFR
(mL/min/1.73 m2/yr)
-2.1 (-10-+12) -2.7 (-28-+16)
Subjects on hemodialysis 2 9*
* for p < 0.05.
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findings, although an important difference is that we
investigated patients with CKD: the prognostic value of
kidney size for these more advanced patients has not
been reported to date. We feel that this result is of
interest, as patients with CKD are likely to undergo an
ultrasound imaging in day-to-day clinical practice. Once
the possibility of obstructive renal disease has been
excluded, about 99% of the ultrasound imaging reports
are classified as normal, whereas they contain interesting
information about the later outcome of the patients.
Renal hypertrophy is an early phenomenon in diabetic
patients: clinical observations show that it precedes
microalbuminuria [12], which is now recognized as a
non-obligatory step as ~20% of renal insufficient dia-
betic patients are normoalbuminuric [33-35]. Baumgartl
indeed mentioned a few cases of renal hypertrophy pre-
ceeding severe renal disease without any abnormal AER
[26]. The underlying pathological abnormalities are
enlarged glomerular volume, which may not be similar
in type 1 and type 2 diabetes [36], and tubular enlarge-
ment [37]; experimental studies suggest that the renal
hypertrophy may be due to the inhibition of kidney
AMP-activated protein kinase by high glucose level [38],
and that it precedes glomerular hyperfiltration [39], giv-
ing rise to it by a tubuloglomerular feedback mechanism
[40]. Although the reversal of renal hypertrophy has
been observed in animals with various treatments, such
as glucose control [41], neutralizing VEGF antibody [42]
or C-peptide [43], human observations are in favor of a
persistence of renal hypertrophy [17,27-29], but its out-
come has yet to be reported in advanced stages of dia-
betic renal disease.
Figure 2 Survival curves of patients with diabetes and CKD, according to their initial kidney length (end-point: dialysis).
Table 2 The renal outcome of the subjects according to
their type of diabetes and kidney size
Type 1 diabetes Type 2 diabetes
n2 0 5 5
age 54 ± 17 65 ± 10°°°
BMI 23.6 ± 3.4 29.8 ± 4.9°°°
Small-108 mm-Large Small-108 mm-Large
n 1 01 02 72 8
Isotopic GFR
(mL/min/1.73 m
2)
59
(20-94)
73
(12-209)
40
(15-129)
60*
(8-154)
Albumin Excretion Rate
(mg/24 H)
98
(20-1080)
196
(32-2312)
137
(20-2358)
390
(28-2010)
Decline of e-GFR
(mL/min/1.73 m
2/yr)
-0.5
(-6-+8)
-2.0
(-8-+16)
-1.1
(-1-+12)
-2.0
(-28-+3)
Dialysis onset 1 2 1 7*
* indicates p < 0.05 vs small kidneys. °°° indicates p < 0.001 vs Type 1.
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mind. Apart from the “hard” endpoint of dialysis
onset, we used an estimation of GFR to measure the
decline in renal function; creatinine-based estimations
(Cockcroft-Gault, MDRD) are known to underestimate
GFR decline in diabetes [44], especially in patients
with mild to moderate renal impairment [32]. For this
reason we used the Mayo Clinic Quadratic equation
that is less biased according to GFR [45] and less
affected by the progression-related biases [46]; the
rates of e-GFR declines however differed significantly
only in the “severe CKD” group (for the comparison
between “small” and “large” kidneys on the whole
group, p = 0.10). Measuring GFR would presumably
have led to greater differences in the less advanced
stages, as reported in the 68 patients who were evalu-
ated twice by Zerbini et al [12]. Another limitation was
that kidney length was measured ultrasonographically
by several observers. Nevertheless, this has been found
to be a reliable method with an acceptable magnitude
of variation when made by a single or different ultraso-
nographers [47]. The kidney lenght is correlated to the
renal volume: it is indeed included in the ellipsoid for-
mula to calculate it [48]. Neither the side (right or left)
nor the patient position (prone or supine) had a signif-
icant influence on this measurement, and its good
reproducibility has also been reported in patients with
large kidneys due to polycystic kidney disease [49].
Further work will be necessary to confirm our findings
in other cohorts, and to determine whether the thresh-
o l do fk i d n e yl e n g t ht h a tw ef o u n di sar e p r o d u c i b l e
indicator of progression according to the level of renal
function.
Conclusions
Large kidneys still predict progression in advanced CKD
complicating diabetes. In these patients, ultrasound
imaging not only excludes obstructive renal disease, but
also provides information on the progression of the
renal disease,
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